Pfizer COVID Antiviral Use Jumped 315 Percent

Published on May 17, 2022

Imagine you have a favorite ice cream flavor that suddenly becomes incredibly popular. Everyone is lining up to get a taste! Well, that’s what happened with Pfizer’s COVID-19 oral antiviral treatment, Paxlovid. In just the past four weeks, its use skyrocketed by a jaw-dropping 315%! It’s like going from a quiet neighborhood road to a bustling highway filled with cars at rush hour. The U.S. Department of Health and Human Services revealed that over 115,000 courses of the pills were dispensed during the first week of May alone. That’s a lot of individuals taking steps to protect themselves against COVID-19. With Paxlovid’s growing popularity, it’s clear that people are seeking effective treatments to fight the virus. This surge in use may indicate both an increase in COVID-19 cases and more awareness of treatment options. Whatever the reason, it’s exciting to see advancements being made in our battle against the pandemic! Want to learn more about Pfizer’s antiviral treatment? Check out the full article for all the juicy details.

Use of Pfizer Inc’s COVID-19 oral antiviral treatment Paxlovid has jumped 315% over the past four weeks, the U.S. Department of Health and Human Services said on Tuesday. Nearly 115,000 courses of the pills were dispensed during the first week of May, a senior health…

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>